Pharma giants make progress in pivot to mRNA technology in race for next-gen influenza vaccines, but hurdles remain

[Image courtesy of Adobe Stock]

mRNA technology helped propel the development of some of the most successful drugs in pharma history — notably, the Comirnaty COVID-19 from Pfizer generated almost $56 billion in 2022 while Moderna’s Spikevax vaccine raked in $18.4 billion. But with demand for COVID-19 vaccines cooling, drug developers are aiming to extend the dominion of mRNA technology to flu vaccines. This month, Moderna and the CureVac/GSK alliance announced promising interim results for their respective flu vaccine candidates. Meanwhile, a year ago, in September 2022, Pfizer announced a phase 3 study for its mRNA-based influenza vaccine. NIH is also developing an mRNA vaccine that promises to provide protection against all known influenza subtypes. A phase 1 study of it is underway.

Sanofi has acknowledged the promise and perils of mRNA flu vaccines

Sanofi, a prominent flu vaccine maker, has acknowledge…

Read more
  • 0